Dermatology Medical News about Ceftobiprole

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections
Expert Review of Anti-infective Therapy, 09/11/09

Schirmer PL et al. – Ceftobiprole is among the first of a new generation of cephalosporins with activity against aerobic Gram–negative bacilli, which extends to cefepime–sensitive Pseudomonas aeruginosa, and activity against Gram–positive organisms, which includes methicillin–resistant Staphylococcus aureus. Ceftobiprole is currently undergoing evaluation by the US FDA for the treatment of complicated skin and skin structure infections, with a decision pending further evaluation of study site monitoring. It is also being evaluated for the treatment of community–acquired and healthcare–associated pneumonia. Two Phase III multicenter trials have demonstrated noninferiority in complicated skin and skin structure infections when tested against vancomycin in primarily Gram–positive bacterial infections, and when tested against vancomycin plus ceftazidime in Gram–positive and Gram–negative bacterial infections. It is well tolerated, with the most common side effects being nausea and dysgeusia.

<< Previous
Simultaneous determination of heavy metals in cosmetic products

Next >>
Roughness analysis of the skin as a secondary evaluation...